Active ingredientOclacitinibCat. No. P-O003-001CAS 1208319-26-9Family · Pharmaceutical analytical standards
Oclacitinib
A Janus kinase inhibitor, mainly selective for JAK1, developed for dogs: approved in the United States in 2013, it controls itching from allergic dermatitis and atopic dermatitis. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?It works fast: in most dogs itching eases within about four hours and is gone within 24, because it dampens the signals of itch cytokines such as IL-31.
Go to the active ingredient →Active ingredientOclacitinibCat. No. P-O003-001CAS 1208319-26-9
Active ingredientOclacitinib MaleateCat. No. P-O003-002CAS 1208319-27-0
Isotopically labelledOclacitinib-13C-d3Cat. No. P-O003-003CAS 2750534-84-8
ImpurityOclacitinib Maleate cis-isomerCat. No. P-O003-004No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.